Targeting m6A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo
AbstractEpigenetic editing, particularly N6-methyladenosine (m6A) modification, represents a promising therapeutic strategy by silencing genes without altering DNA sequence. However, in vivo epigenetic intervention of neuroinflammation remains challenging and has rarely been explored. Here we developed a hybrid epigenetic nanomodulator, siMETTL3-hNVs, by integrating natural microglia-derived na...
Read More